Advertisement

ADVERTISEMENT

quality of life

Research in Review
Stereotactic Ablative Radiation Therapy Effective in Treating Kidney Cancer
05/08/2017
JCP Editors
Stereotactic ablative radiation therapy can achieve more than 90% control of renal cell carcinoma metastases, according to a study published in the International Journal of Radiation Oncology, Biology, and Physics...
Stereotactic ablative radiation therapy can achieve more than 90% control of renal cell carcinoma metastases, according to a study published in the International Journal of Radiation Oncology, Biology, and Physics...
...
05/08/2017
Journal of Clinical Pathways
Department
Cancer Patients Unfamiliar With Clinical Practice Guidelines, Clinical Pathways
04/12/2017
JCP Editors
Results of a recent survey of the cancer care experience revealed barriers to navigating cancer care, including high costs and lack of information about how treatment decisions are made. ----- Related...
Results of a recent survey of the cancer care experience revealed barriers to navigating cancer care, including high costs and lack of information about how treatment decisions are made. ----- Related...
...
04/12/2017
Journal of Clinical Pathways
Research in Review
Neurofeedback Reduces Nerve Damage From Chemotherapy in Cancer Survivors
04/11/2017
JCP Editors
Chemotherapy-induced peripheral neuropathy (CIPN) may be significantly reduced by electroencephalogram (EEG) neurofeedback training, according to research published in Cancer (published online March 3, 2017;...
Chemotherapy-induced peripheral neuropathy (CIPN) may be significantly reduced by electroencephalogram (EEG) neurofeedback training, according to research published in Cancer (published online March 3, 2017;...
...
04/11/2017
Journal of Clinical Pathways
Research in Review
Daratumumab Cost-Effective for Refractory Multiple Myeloma
04/10/2017
JCP Editors
Single agent daratumumab may serve as a more cost-effective treatment strategy than pomalidomide for patients with refractory multiple myeloma. ----- Related Content Daratumumab improves progression-free survival...
Single agent daratumumab may serve as a more cost-effective treatment strategy than pomalidomide for patients with refractory multiple myeloma. ----- Related Content Daratumumab improves progression-free survival...
Single...
04/10/2017
Journal of Clinical Pathways
Research in Review
New Drug Improves PFS for Patients With ALK-Positive NSCLC
04/10/2017
JCP Editors
Patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) live significantly longer without disease progression when treated with a new drug compared with those treated with...
Patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) live significantly longer without disease progression when treated with a new drug compared with those treated with...
...
04/10/2017
Journal of Clinical Pathways
Research in Review
Shorter Radiotherapy Regimen Effective in Treating Localized Prostate Cancer
03/20/2017
JCP Editors
A 4-week precision radiotherapy regimen is as effective and safe as the standard 8-week regimen for treating localized prostate cancer, according to research published in the Journal of Clinical Oncology (published...
A 4-week precision radiotherapy regimen is as effective and safe as the standard 8-week regimen for treating localized prostate cancer, according to research published in the Journal of Clinical Oncology (published...
A...
03/20/2017
Journal of Clinical Pathways
Research in Review
Neurofeedback Reduces Nerve Damage From Chemo in Cancer Survivors
03/13/2017
JCP Editors
Chemotherapy-induced peripheral neuropathy (CIPN) may be significantly reduced by electroencephalogram (EEG) neurofeedback training, according to research published in Cancer (published online March 3, 2017;...
Chemotherapy-induced peripheral neuropathy (CIPN) may be significantly reduced by electroencephalogram (EEG) neurofeedback training, according to research published in Cancer (published online March 3, 2017;...
...
03/13/2017
Journal of Clinical Pathways
Research in Review
TKI Discontinuation Improves Remission Rates for Patients With CML
03/03/2017
JCP Editors
Patients with chronic myeloid leukemia (CML) who discontinued treatment with second-generation tyrosine kinase inhibitors (TKIs) benefited from significant treatment-free remission rates, according to research...
Patients with chronic myeloid leukemia (CML) who discontinued treatment with second-generation tyrosine kinase inhibitors (TKIs) benefited from significant treatment-free remission rates, according to research...
...
03/03/2017
Journal of Clinical Pathways
Perspectives
Patient-Reported Outcome Measurement in Clinical Practice: Overcoming Challenges to Continue Progress
02/13/2017
Rahma Warsame, MD
Michele Y Halyard, MD
Abstract: Health systems are evolving to make the patient the central focus of health care delivery. This has resulted in increased use and interest in patient-reported outcomes (PROs) to include the patient’s...
Abstract: Health systems are evolving to make the patient the central focus of health care delivery. This has resulted in increased use and interest in patient-reported outcomes (PROs) to include the patient’s...
...
02/13/2017
Journal of Clinical Pathways
Research in Review
Cost-Effectiveness of Non–Guideline-Adherent Treatments Varies
02/13/2017
JCP Editors
Treatment preferences that do not adhere to clinical guidelines may still be cost-effective, according to a series of recently published case reports. Patients preferences for treatment sometimes divert from...
Treatment preferences that do not adhere to clinical guidelines may still be cost-effective, according to a series of recently published case reports. Patients preferences for treatment sometimes divert from...
...
02/13/2017
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Upcoming Events

September 21 ⁠–⁠ September 22
AMP Europe
September 30 ⁠–⁠ October 2
October 1 ⁠–⁠ October 2
SAWC Fall
October 2 ⁠–⁠ October 5
October 5 ⁠–⁠ October 6
SMASH
October 14 ⁠–⁠ October 16
Lymphoma, Leukemia, and Myeloma
October 16 ⁠–⁠ October 19
October 19 ⁠–⁠ October 20
October 26 ⁠–⁠ October 27
October 29 ⁠–⁠ November 2
See Full Calendar

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use